Payment overview · 2025
General Payments
$665.83
29 reported records · 15 companies
Healthcare provider profile · identity verified
Brian J Candell, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ORINDA, CA · NPI 1164581575
Verified facts
What the public records show
CMS Open Payments records show Brian J Candell, M.D. received $665.83 in general payments during 2025 across 29 reported records.
Lilly USA, LLC accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $160.70 | 24.1% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.96 | 10.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $57.65 | 8.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.77 | 8.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.80 | 7.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.31 | 6.7% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.16 | 6.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $32.06 | 4.8% | 1 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $31.01 | 4.7% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $27.74 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.87 | 3.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.64 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.85 | 2.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.42 | 2.5% | 1 | 2025 |
| Bavarian Nordic A/S | Unresolved — no canonical attribution shown | $15.89 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $665.83 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $160.70 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $160.70 | 8 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $57.65 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $52.80 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.55 | 2 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $32.06 | 1 | 2025 |
Source payment records
|
|||||
| XACDURO Normalized: xacduro |
Drug | La Jolla Pharmaceutical Company | $31.01 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $29.45 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $27.74 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $27.74 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| Vivotif Normalized: vivotif |
Drug | Bavarian Nordic A/S | $15.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
72 | 68 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 782 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 405 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 367 | 94 |
| Zolpidem Tartrate | Zolpidem Tartrate | 346 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 46 |
| Lisinopril | Lisinopril | 224 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 54 |
| Simvastatin | Simvastatin | 192 | 57 |
| Trazodone Hcl | Trazodone Hcl | 179 | 45 |
| Lorazepam | Lorazepam | 177 | 51 |
| Alendronate Sodium | Alendronate Sodium | 147 | 34 |
| Losartan Potassium | Losartan Potassium | 142 | 35 |
| Eliquis | Apixaban | 131 | 23 |
| Sertraline Hcl | Sertraline Hcl | 121 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 35 |
| Allopurinol | Allopurinol | 100 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 20 |
| Metformin Hcl | Metformin Hcl | 93 | 25 |
| Azithromycin | Azithromycin | 86 | 72 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 24 |
| Bupropion Xl | Bupropion Hcl | 84 | 21 |
| Atenolol | Atenolol | 83 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 23 |
| Furosemide | Furosemide | 74 | 19 |
| Jardiance | Empagliflozin | 74 | 20 |
| Gabapentin | Gabapentin | 73 | 22 |
| Paxlovid | Nirmatrelvir/Ritonavir | 72 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 23 |
| Prednisone | Prednisone | 70 | 33 |
| Synthroid | Levothyroxine Sodium | 66 | 17 |
| Alprazolam | Alprazolam | 65 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 51 |
| Ozempic | Semaglutide | 59 | suppressed |
| Omeprazole | Omeprazole | 56 | 21 |
| Valsartan | Valsartan | 56 | 17 |
| Finasteride | Finasteride | 51 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 13 |
| Estradiol | Estradiol | 46 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Celecoxib | Celecoxib | 42 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | 11 |
| Testosterone | Testosterone | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 38 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 24 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 15 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 17 |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 29 | 29 |
| Diazepam | Diazepam | 29 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Colchicine | Colchicine | 19 | 11 |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | 14 |
| Atovaquone-Proguanil Hcl | Atovaquone/Proguanil Hcl | 18 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Zaleplon | Zaleplon | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Ambien | Zolpidem Tartrate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Zolmitriptan | Zolmitriptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $665.83 · 29 records | Lilly USA, LLC | AIRSUPRA, AREXVY, AVYCAZ, CAPVAXIVE, CUVITRU, DALVANCE, EMBLAVEO, GARDASIL 9, JARDIANCE, LOREEV XR, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, TEFLARO, TERIPARATIDE, The Cologuard Plus Collection Kit, Vivotif, XACDURO, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error